FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1968941521> ?p ?o ?g. }

• W1968941521 endingPage "401" @default.
• W1968941521 startingPage "397" @default.
• W1968941521 abstract "BackgroundIn a recent large phase III study, previously treated patients with advanced non-small cell lung cancer who received pemetrexed demonstrated a survival time similar to patients who received docetaxel (median, 8.3 months with pemetrexed versus 7.9 months with docetaxel), with a more favorable toxicity profile, and significantly fewer Common Toxicity Criteria grade 3/4 toxicities. This is a retrospective risk-benefit analysis of survival without grade 3/4 toxicity, defined as the time to the first occurrence of Common Toxicity Criteria grade 3 or 4 toxicity or death, in the prospective phase III study comparing pemetrexed with docetaxel.MethodsA total of 541 patients (of 571 randomized) received either pemetrexed (500 mg/m2 intravenously [IV]) supplemented with vitamin B12 injections and oral folic acid or docetaxel (75 mg/m2 IV) on day 1 of 21-day cycles. Survival without grade 3/4 toxicity was analyzed using Kaplan-Meier and Cox methods.ResultsPemetrexed demonstrated a statistically significantly longer survival without grade 3/4 toxicity compared with docetaxel (hazard ratio = 0.60, 95% confidence interval: 0.50–0.72; p < 0.0001). A supportive analysis based on selected grade 3/4 toxicities (neutropenia lasting >5 days, febrile neutropenia, infection with neutropenia, anemia, thrombocytopenia, fatigue, nausea, vomiting, diarrhea, stomatitis, and neurosensory events) also demonstrated an advantage for pemetrexed (hazard ratio = 0.53; 95% confidence interval: 0.44–0.64; p < 0.0001).ConclusionThis analysis of survival without grade 3/4 toxicity suggests a benefit-to-risk profile that favors pemetrexed over docetaxel in the second-line treatment of patients with non-small cell lung cancer. In a recent large phase III study, previously treated patients with advanced non-small cell lung cancer who received pemetrexed demonstrated a survival time similar to patients who received docetaxel (median, 8.3 months with pemetrexed versus 7.9 months with docetaxel), with a more favorable toxicity profile, and significantly fewer Common Toxicity Criteria grade 3/4 toxicities. This is a retrospective risk-benefit analysis of survival without grade 3/4 toxicity, defined as the time to the first occurrence of Common Toxicity Criteria grade 3 or 4 toxicity or death, in the prospective phase III study comparing pemetrexed with docetaxel. A total of 541 patients (of 571 randomized) received either pemetrexed (500 mg/m2 intravenously [IV]) supplemented with vitamin B12 injections and oral folic acid or docetaxel (75 mg/m2 IV) on day 1 of 21-day cycles. Survival without grade 3/4 toxicity was analyzed using Kaplan-Meier and Cox methods. Pemetrexed demonstrated a statistically significantly longer survival without grade 3/4 toxicity compared with docetaxel (hazard ratio = 0.60, 95% confidence interval: 0.50–0.72; p < 0.0001). A supportive analysis based on selected grade 3/4 toxicities (neutropenia lasting >5 days, febrile neutropenia, infection with neutropenia, anemia, thrombocytopenia, fatigue, nausea, vomiting, diarrhea, stomatitis, and neurosensory events) also demonstrated an advantage for pemetrexed (hazard ratio = 0.53; 95% confidence interval: 0.44–0.64; p < 0.0001). This analysis of survival without grade 3/4 toxicity suggests a benefit-to-risk profile that favors pemetrexed over docetaxel in the second-line treatment of patients with non-small cell lung cancer." @default.
• W1968941521 created "2016-06-24" @default.
• W1968941521 creator A5018952767 @default.
• W1968941521 creator A5035353381 @default.
• W1968941521 creator A5041989947 @default.
• W1968941521 creator A5055787566 @default.
• W1968941521 creator A5073571977 @default.
• W1968941521 creator A5086408994 @default.
• W1968941521 creator A5089930850 @default.
• W1968941521 date "2007-05-01" @default.
• W1968941521 modified "2023-10-16" @default.
• W1968941521 title "Survival without Common Toxicity Criteria Grade 3/4 Toxicity for Pemetrexed Compared with Docetaxel in Previously Treated Patients with Advanced Non-small Cell Lung Cancer (NSCLC): A Risk-Benefit Analysis" @default.
• W1968941521 cites W1686570062 @default.
• W1968941521 cites W1988007280 @default.
• W1968941521 cites W2020159902 @default.
• W1968941521 cites W2059645245 @default.
• W1968941521 cites W2073979951 @default.
• W1968941521 cites W2076668534 @default.
• W1968941521 cites W2130652363 @default.
• W1968941521 cites W2134667653 @default.
• W1968941521 cites W2145653040 @default.
• W1968941521 cites W4293241248 @default.
• W1968941521 doi "https://doi.org/10.1097/01.jto.0000268672.57002.69" @default.
• W1968941521 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17473654" @default.
• W1968941521 hasPublicationYear "2007" @default.
• W1968941521 type Work @default.
• W1968941521 sameAs 1968941521 @default.
• W1968941521 citedByCount "59" @default.
• W1968941521 countsByYear W19689415212012 @default.
• W1968941521 countsByYear W19689415212013 @default.
• W1968941521 countsByYear W19689415212014 @default.
• W1968941521 countsByYear W19689415212015 @default.
• W1968941521 countsByYear W19689415212016 @default.
• W1968941521 countsByYear W19689415212017 @default.
• W1968941521 countsByYear W19689415212018 @default.
• W1968941521 countsByYear W19689415212019 @default.
• W1968941521 countsByYear W19689415212020 @default.
• W1968941521 countsByYear W19689415212021 @default.
• W1968941521 countsByYear W19689415212022 @default.
• W1968941521 crossrefType "journal-article" @default.
• W1968941521 hasAuthorship W1968941521A5018952767 @default.
• W1968941521 hasAuthorship W1968941521A5035353381 @default.
• W1968941521 hasAuthorship W1968941521A5041989947 @default.
• W1968941521 hasAuthorship W1968941521A5055787566 @default.
• W1968941521 hasAuthorship W1968941521A5073571977 @default.
• W1968941521 hasAuthorship W1968941521A5086408994 @default.
• W1968941521 hasAuthorship W1968941521A5089930850 @default.
• W1968941521 hasBestOaLocation W19689415211 @default.
• W1968941521 hasConcept C126322002 @default.
• W1968941521 hasConcept C141071460 @default.
• W1968941521 hasConcept C143998085 @default.
• W1968941521 hasConcept C207103383 @default.
• W1968941521 hasConcept C2776256026 @default.
• W1968941521 hasConcept C2776694085 @default.
• W1968941521 hasConcept C2777063308 @default.
• W1968941521 hasConcept C2777240266 @default.
• W1968941521 hasConcept C2778239845 @default.
• W1968941521 hasConcept C2778850193 @default.
• W1968941521 hasConcept C2781190966 @default.
• W1968941521 hasConcept C29730261 @default.
• W1968941521 hasConcept C44249647 @default.
• W1968941521 hasConcept C71924100 @default.
• W1968941521 hasConcept C90924648 @default.
• W1968941521 hasConceptScore W1968941521C126322002 @default.
• W1968941521 hasConceptScore W1968941521C141071460 @default.
• W1968941521 hasConceptScore W1968941521C143998085 @default.
• W1968941521 hasConceptScore W1968941521C207103383 @default.
• W1968941521 hasConceptScore W1968941521C2776256026 @default.
• W1968941521 hasConceptScore W1968941521C2776694085 @default.
• W1968941521 hasConceptScore W1968941521C2777063308 @default.
• W1968941521 hasConceptScore W1968941521C2777240266 @default.
• W1968941521 hasConceptScore W1968941521C2778239845 @default.
• W1968941521 hasConceptScore W1968941521C2778850193 @default.
• W1968941521 hasConceptScore W1968941521C2781190966 @default.
• W1968941521 hasConceptScore W1968941521C29730261 @default.
• W1968941521 hasConceptScore W1968941521C44249647 @default.
• W1968941521 hasConceptScore W1968941521C71924100 @default.
• W1968941521 hasConceptScore W1968941521C90924648 @default.
• W1968941521 hasIssue "5" @default.
• W1968941521 hasLocation W19689415211 @default.
• W1968941521 hasLocation W19689415212 @default.
• W1968941521 hasOpenAccess W1968941521 @default.
• W1968941521 hasPrimaryLocation W19689415211 @default.
• W1968941521 hasRelatedWork W1668780299 @default.
• W1968941521 hasRelatedWork W2039384550 @default.
• W1968941521 hasRelatedWork W2106964779 @default.
• W1968941521 hasRelatedWork W2130953775 @default.
• W1968941521 hasRelatedWork W2134667653 @default.
• W1968941521 hasRelatedWork W2152237079 @default.
• W1968941521 hasRelatedWork W2167650070 @default.
• W1968941521 hasRelatedWork W2572035171 @default.
• W1968941521 hasRelatedWork W4235400347 @default.
• W1968941521 hasRelatedWork W4376870566 @default.
• W1968941521 hasVolume "2" @default.
• W1968941521 isParatext "false" @default.
• W1968941521 isRetracted "false" @default.
• W1968941521 magId "1968941521" @default.
• W1968941521 workType "article" @default.